Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
UK Gastroenterology Devices Market Size, Share, Growth, Trends, and Global Industry Analysis: By Device Type, By End-User, and Country Forecast 2020-2031
UK Gastroenterology Devices Market size was valued at US$ 1,230 million in 2024 and is expected to reach US$ 1,750 million by 2031, growing at a significant CAGR of 5.1% from 2025-2031. The British gastroenterology devices market is continually evolving due to increasing demand for increasingly GI disorders and an aging population increasingly exposed to chronic digestive disorders. From colonoscopy equipment to endoscopic ultrasound and capsule endoscopy technology, the sector has a blend of varied technology used to aid timely diagnosis and minimally invasive treatments. In an NHS setting committed to early diagnosis, patient comfort, and effective systems, these devices are increasingly popular in NHS hospitals and private clinics nationwide. Other colorectal cancer screening schemes and elevated awareness of gut health are also driving new diagnostic and treatment device adoption throughout the UK.
Beyond clinical necessity, the market is driven by a combination of technological innovation, procedure convergence, and policy reform in the healthcare space. UK medtech firms and overseas companies are betting on AI-powered endoscopy, wireless capsule imaging, and intelligent biopsy tools for enhanced precision and reduced patient risk. With this, NHS modernization efforts such as digitalization of diagnostic pathways and increased investment in digestive disease programs are creating a favorable atmosphere for the penetration of devices. While regulatory channels post-Brexit continue to be uncertain, UK's emphasis on medicinal innovation and public-private models of healthcare is provision that guarantees the market for gastroenterology devices will be vibrant and rife with opportunities.
Based on the device type:
Among all the many gastroenterology instruments employed across the UK, biopsy forceps are still one of the most essential instruments applied in diagnostic endoscopy. Gastroenterologists use these instruments more than any others because they are versatile, reliable, and effective at producing high-quality tissue samples in normal and difficult procedures. The instruments are especially crucial in screening protocols for colorectal cancer, where accuracy in procurement is directly related to the diagnosis. These are being refined by makers in an effort to make them more ergonomic, more under grip control, and more suited for high-definition scopes. Their widespread usage in diagnostic and therapeutic use together with greater emphasis on initial mucosal examination favors biopsy forceps as the most consistently utilized form of device used in GI endoscopy procedures.
Based on the end user:
NHS Trusts rely on increasingly varied configurations of high performance and financially viable equipment in order to facilitate standards of care within their tightly stretched operating budgets. The central purchasing scheme enables economies of scale but, conversely, also engenders high performance expectation, begetting high expectations of simplicity of sterility and reliability. With greater emphasis on day-one diagnostics and backlog clearing since COVID, NHS trusts are seeking medtech solutions that enable procedure efficacy at the expense of clinical performance, making them a key target for medtech innovation and collaboration. By Country – England England leads the market through its high population density of teaching hospitals, advanced endoscope units, and high population awareness of digestive health
Rising incidence of gastrointestinal disease, i.e., colorectal cancer, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD), among an aging population is one of the key drivers of the market. The NHS has been stressing early diagnosis through national screening programs, which has gone to play to boost directly demand for advanced diagnostic tools like endoscopic imaging equipment and biopsy forceps. At the same time, changed eating habits, stress, and a lack of exercise are resulting in increased numbers of GI discomfort cases among the younger population groups, extending the patient demographic.
Clinicians in the UK are overwhelmingly opting for precision and minimally invasive devices with lower post-procedure recovery times and the capability for faster throughput, particularly timely with the increasing NHS focus on operational effectiveness and elimination of backlogs post-COVID
While it possesses high future strength, the market is also inclined to be under some structural limitations that influence overall momentum. Excessively high cost of expenditure on GI devices with endoscopic and robotic support discourages buying by mid-sized and small healthcare organizations. Furthermore, sustained fiscal conservatism in the NHS leads to delay for device adoption, especially for non-emergency care streams. Post-Brexit regulatory pressure has also thrown another spanner into the works because manufacturers are now enjoying longer times of authorization as they've been released from EU MDR controls. T
his limited technical training on advanced gastroenterology equipment, particularly in distant or under-resourced Trusts, is another limiting factor for adoption. These all combine to slow rollout of more advanced technology and, as a consequence, slow clinical integration even where benefit has been proven.
Technological innovation and policy-led modernization are fertile ground for growth. British government investment in AI and digital healthcare is paving the way for new avenues of intelligent gastroenterology diagnosis, particularly AI-powered colonoscopy and machine learning-based imaging interpretation. In addition, increasing demand for public-private partnerships is improving access to next-generation technology, as NHS Trusts engage with medtech companies on trial projects and equipment leasing initiatives.
The increasing home use of capsule endoscopy kits has the potential to revolutionize patient participation and continuity of care even in outpatient settings. Private care is also experiencing higher demand for complex GI procedures, hence creating a secondary growth opportunity. These trends indicate that companies with adaptive pricing structures, scalable technologies, and UK-centric tailored regulatory approaches are best well placed to succeed.
One of the most powerful trends in the market is the faster adoption of artificial intelligence (AI) for endoscopic imaging. Hospitals and diagnostic facilities are increasingly looking at AI-enabled colonoscopy systems that can detect polyps and mucosal lesions in real-time with higher sensitivity than conventional methods. Not only do such digitally printed overlays improve diagnostic precision, but also aid in reducing missed lesions, a chronic issue with traditional colonoscopy procedures.
Furthermore, the technology also reduces physician fatigue and enables standardization of diagnostic results, especially valuable in busy NHS settings. Growing clinical trust in AI, combined with its potential for saving long-term spend through intervention at an earlier phase, is turning it into a game-changing force driving GI diagnosis across the UK.
Report Benchmarks |
Details |
Market Size in 2024 |
US$ 1,230 million |
Market Size in 2031 |
US$ 1,750 million |
By Device Type |
|
By End User |
|
According to PBI Analyst, the market is evolving rapidly as public and private healthcare systems focus on early diagnosis, minimally invasive care, and workflow efficiency. The NHS’s push for faster diagnostic turnaround, especially post-COVID, has accelerated demand for devices that combine precision with operational adaptability. While biopsy forceps continue to anchor most diagnostic procedures, the market is seeing heightened interest in AI-integrated imaging, capsule-based diagnostics, and multi-functional endoscopic tools. Innovation partnerships between medtech firms and NHS Trusts are becoming a key mechanism for adoption.
Although regulatory complexity and procurement costs pose constraints, firms that align with NHS efficiency goals and invest in clinician-friendly technology are well positioned to lead this dynamic and opportunity-rich space.
Download Free Sample Report
The UK gastroenterology devices market size was valued at US$ 1,230 million in 2024 and is projected to grow at a significant CAGR of 5.1% from 2025-2031.
Rising prevalence of gastrointestinal disorders, expansion of national screening programs, and growing preference for minimally invasive diagnostics are driving market growth.
The integration of artificial intelligence in endoscopic imaging is emerging as a major trend, offering real-time detection accuracy and improving clinical outcomes.
Market research is segmented based on device type, end-user
1.Executive Summary |
2. Uk Gastroenterology Devices Market Introduction |
2.1. Uk Gastroenterology Devices Market - Taxonomy |
2.2. Uk Gastroenterology Devices Market - Definitions |
2.2.1.Type |
2.2.2.Application |
3. Uk Gastroenterology Devices Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Uk Gastroenterology Devices Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Uk Gastroenterology Devices Market By Type , 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Biopsy Forceps |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Snares |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Injection Needles |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Cleaning & Decontamination |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. EMR/ Esd |
5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. ERCP |
5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. ESU |
5.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Others |
5.8.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
6. Uk Gastroenterology Devices Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. NHS Hospitals |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Private Hospitals |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Competition Landscape |
7.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
7.2.1.Steris Plc |
7.2.2.Diagmed Healthcare |
7.2.3.Medtronic Plc |
7.2.4.Boston Scientific Corporation |
7.2.5.HOYA Corporation |
7.2.6.Olympus Corporation |
7.2.7.Fujifilm Holdings Corporation |
7.2.8.CONMED Corporation |
7.2.9.Karl Storz GmbH & Co. KG |
7.2.10.Medrobotics Corporation & Co. |
8. Research Methodology |
9. Appendix and Abbreviations |
Key Market Players